Posted by Diabetes South Texas Staff
Clinical Trial News
Sunday, March 2nd, 2014
Pharma: Washington, D.C. (February 11, 2014) — America’s biopharmaceutical research companies currently are developing 180 innovative new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 30 for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).
In the United States, nearly 26 million patients are affected by diabetes. The disease is one of the leading killers of Americans and the epidemic is quickly escalating. According to the Centers for Disease Control and Prevention (CDC), the prevalence of diabetes among U.S. adults grew by 45 percent over the past 20 years. Today, one in 10 American adults has diabetes and as many as one in three could face the disease by 2050 if the current trends continue. Read More
Posted by Diabetes South Texas Staff
Clinical Trial News
Sunday, March 2nd, 2014
Diabetes Care February 10, 2014
OBJECTIVE To test whether the implementation of elements of the Chronic Care Model (CCM) via a specially trained practice nurse leads to an improved cardiovascular risk profile among type 2 diabetes patients.
RESEARCH DESIGN AND METHODS This cluster randomized controlled trial with primary care physicians as the unit of randomization was conducted in the German part of Switzerland. Three hundred twenty-six type 2 diabetes patients (age >18 years; at least one glycosylated hemoglobin [HbA1c] level of ≥7.0% [53 mmol/mol] in the preceding year) from 30 primary care practices participated. The intervention included implementation of CCM elements and involvement of practice nurses in the care of type 2 diabetes patients. Primary outcome was HbA1c levels. Read More
Posted by Diabetes South Texas Staff
Clinical Trial News
Sunday, March 2nd, 2014
Diabetes Care: March 2014
OBJECTIVE The extracellular matrix protein fibulin-1 is upregulated in the arterial wall in type 2 diabetes (T2D) and circulates in increased concentrations in diabetes. Metformin is an antidiabetic drug with beneficial cardiovascular disease effects in diabetes. We hypothesized that metformin would influence the increased level of plasma fibulin-1 in diabetes.
RESEARCH DESIGN AND METHODS After a 4-week run-in period, 371 eligible patients with T2D were randomized to treatment groups in a factorial design including insulin alone (control), +metformin, +rosiglitazone, or +both metformin and rosiglitazone. Plasma fibulin-1 was analyzed at the beginning of the study and after 18 and 24 months. Read more
Posted by Diabetes South Texas Staff
Clinical Trial News
Sunday, March 2nd, 2014
Diabetes Care: March 2014
OBJECTIVE No prospective trials have been carried out comparing antibiotic treatment alone with primarily surgical treatment in patients with diabetes and foot osteomyelitis. The aim of the current study was to compare the outcomes of the treatment of diabetic foot osteomyelitis in patients treated exclusively with antibiotics versus patients who underwent conservative surgery, following up the patients for a period of 12 weeks after healing.
RESEARCH DESIGN AND METHODS Between 1 January 2010 and 31 December 2012, a prospective randomized comparative trial (clinical trial reg. no. NCT01137903,clinicaltrials.gov) of patients with diabetes who had received a diagnosis of neuropathic foot ulcers complicated by osteomyelitis was carried out at the Diabetic Foot Unit at the Complutense University of Madrid. Patients were randomized into the following two groups: the antibiotics group (AG) and the surgical group (SG). Antibiotics were given for a period of 90 days in the AG. Patients in the SG received conservative surgery with postoperative antibiotic treatment for 10 days. Read more
Posted by Diabetes South Texas Staff
News
Sunday, March 2nd, 2014
Diabetes Care: March 2014
OBJECTIVE The rationale for this study was to review the data on microalbuminuria (MA), an amount of albumin in the urine of 30–299 mg/day, in patients with diabetes in the context of cardiovascular risk and development of kidney disease. The objective was to review the pathophysiology of MA in patients with diabetes and review the data from trials regarding MA in the context of risk for cardiovascular events or kidney disease progression.
RESEARCH DESIGN AND METHODS Data sources were all PubMed-referenced articles in English-language peer-reviewed journals since 1964. Studies selected had to have a minimum 1-year follow-up and be either a randomized trial linking MA to cardiovascular or kidney disease outcome, a meta-analysis/systematic review, or a large observational cohort study. Read More
Posted by Diabetes South Texas Staff
News
Sunday, March 2nd, 2014
American Journal of Public Health: Aug 29, 2013
Tobenna D. Anekwe, ScD, and Ilya Rahkovsky, PhDThe authors are with the Economic Research Service, US Department of Agriculture, Washington, DC.
Correspondence should be sent to Tobenna Anekwe, Economic Research Service, US Department of Agriculture, 1400 Independence Ave SW, Washington, DC 20250-1800 (e-mail:
tanekwe@ers.usda.gov). Reprints can be ordered at
http://www.ajph.org by clicking the “Reprints” link.
Note. The views expressed herein are those of the authors and may not be attributed to the Economic Research Service or the US Department of Agriculture. Read More
Posted by Diabetes South Texas Staff
News
Sunday, March 2nd, 2014
JAMA: February 12, 2014
The widespread concern over the increasing prevalence of obesity and associated diabetes, cardiovascular disease, and some forms of cancer has led in part to a new emphasis on the prevention and control of noncommunicable diseases (NCDs).1 Noncommunicable diseases are a challenge in developed countries but, even more, in developing countries where increasing urbanization and socioeconomic changes lead to the adoption of a sedentary lifestyle, unhealthy diet, smoking, stressful behavior, and exposure to other risk factors such as pollutants. Not only is the prevalence of NCDs increasing, but these disorders are being observed in younger members of the population,2 for whom the long-term costs of health care, loss of earnings, and social consequences are likely to have devastating effects. Read more
